Delcath Systems, Inc. (NASDAQ:DCTH)

Delcath Systems, Inc. (Delcath), incorporated in August 1988, is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver. In February 2012, the Company commenced its first European patient treatments with the CHEMOSAT system at European Institute of Oncology (IEO) in Italy and Frankfurt University Hospital in Germany.